As research continues to explore B cell autoimmunity, B cell-mediated therapies likely will pursue increasingly specific targets, says Arthur Kavanaugh, M.D.
Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence
The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis
Abeona Submits Biologics License Application to FDA for EB-101
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Severe Psoriasis Associated With Higher Risk of Heart Disease
Combination Surgery Plus Adalimumab More Clincially Effective in HS Than Adalimumab Alone
2 Clarke Drive Cranbury, NJ 08512